FNCH Stock Overview
A clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Finch Therapeutics Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.40 |
| 52 Week High | US$14.26 |
| 52 Week Low | US$0.80 |
| Beta | 1.34 |
| 11 Month Change | 3.26% |
| 3 Month Change | 757.14% |
| 1 Year Change | 93.88% |
| 33 Year Change | -97.32% |
| 5 Year Change | n/a |
| Change since IPO | -98.22% |
Recent News & Updates
Recent updates
Finch to cut workforce by about 37% after Takeda ends bowel disease collaboration
Sep 01Finch to get back rights to IBD product candidates after Takeda ends collaboration
Aug 25Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M
Aug 11Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation
Mar 15
Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation
Dec 15We Think Finch Therapeutics Group (NASDAQ:FNCH) Needs To Drive Business Growth Carefully
Aug 28Finch Therapeutics: Gut Instinct Says Buy
Jun 14Shareholder Returns
| FNCH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.9% | 1.4% | 2.6% |
| 1Y | 93.9% | 23.1% | 30.5% |
Return vs Industry: FNCH exceeded the US Biotechs industry which returned 23.1% over the past year.
Return vs Market: FNCH exceeded the US Market which returned 30.5% over the past year.
Price Volatility
| FNCH volatility | |
|---|---|
| FNCH Average Weekly Movement | 42.7% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: FNCH's share price has been volatile over the past 3 months.
Volatility Over Time: FNCH's weekly volatility has increased from 27% to 43% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 1 | Matt Blischak | www.finchtherapeutics.com |
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn’s disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota.
Finch Therapeutics Group, Inc. Fundamentals Summary
| FNCH fundamental statistics | |
|---|---|
| Market cap | US$18.71m |
| Earnings (TTM) | -US$14.17m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.3x
P/E RatioIs FNCH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FNCH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$14.17m |
| Earnings | -US$14.17m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.82 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did FNCH perform over the long term?
See historical performance and comparison